| Brenna M Schillinger, | |
|
1401 S Kendall St, Lakewood, CO 80232-5748 | |
| (303) 982-9720 | |
| Not Available |
| Full Name | Brenna M Schillinger |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1401 S Kendall St, Lakewood, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033634357 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 24378053 (Colorado) | Primary |
| 235Z00000X | Speech-language Pathologist | 242.004404 (Illinois) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Brenna M Schillinger, 1401 S Kendall St, Lakewood, CO 80232-5748 Ph: (303) 982-9720 | Brenna M Schillinger, 1401 S Kendall St, Lakewood, CO 80232-5748 Ph: (303) 982-9720 |
News Archive
Funding earmarked for improving maternal and child health in low- and middle-income countries has grown faster since 2010 than funding for HIV, TB, and malaria.
Increased brain cell apoptosis in intrauterine growth-restricted fetal rats is a key reason for unfavorable long-term prognosis of the nervous system. The harmful effects of intrauterine growth restriction on fetal brain development originate in the womb.
Pathwork Diagnostics, Inc, a privately held molecular diagnostics company focused on oncology, today announced the closing of its $30 million Series C financing. Led by Alta Partners, the financing included participation from the company's existing investors: Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found.
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).
› Verified 7 days ago
Theresa M. Snelling, M.a., Ccc-slp Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9255 W Alameda Ave, Unit C, Lakewood, CO 80226 Phone: 303-232-5711 Fax: 303-232-5711 | |
Patricia Rogers, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13175 W Green Mountain Dr, Lakewood, CO 80228 Phone: 303-982-9500 | |
Jannette Josephine Martin, MA, CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7475 W 5th Ave, Suite 215, Lakewood, CO 80226 Phone: 303-987-1285 | |
Nishma Strode, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2001 Hoyt St, Lakewood, CO 80215 Phone: 303-759-1192 | |
Jami Weinstein, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2800 Youngfield St, Lakewood, CO 80215 Phone: 720-513-0582 | |
Shana Turner Cook, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1940 Willow Ln, Lakewood, CO 80215 Phone: 720-217-5323 |